| [1] |
Llovet JM, Villanueva A, Lachenmayer A, et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era[J]. Nat Rev Clin Oncol, 2015, 12(7):408-424.
|
| [2] |
Niu L, Liu L, Yang S, et al. New insights into sorafenib resistance in hepatocellular carcinoma: responsible mechanisms and promising strategies[J]. Biochim Biophys Acta Rev Cancer, 2017, 1868(2):564-570.
|
| [3] |
Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis:an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5):1060-1072.
|
| [4] |
Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice[J]. Nat Cell Biol, 2014, 16(12):1180-1191.
|
| [5] |
Dolma S, Lessnick SL, Hahn WC, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells[J]. Cancer cell, 2003, 3(3):285-296.
|
| [6] |
Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells[J]. Chem Biol, 2008, 15(3):234-245.
|
| [7] |
Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156(1/2):317-331.
|
| [8] |
Conrad M, Sato H. The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-): cystine supplier and beyond[J]. Amino Acids, 2012, 42(1):231-246.
|
| [9] |
Lewerenz J, Hewett SJ, Huang Y, et al. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities[J]. Antioxid Redox Signal, 2013, 18(5):522-555.
|
| [10] |
Yagoda N, von Rechenberg M, Zaganjor E, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels[J]. Nature, 2007, 447(7146):864-868.
|
| [11] |
Brigelius-Flohé R, Maiorino M. Glutathione peroxidases[J]. Biochim Biophys Acta, 2013, 1830(5):3289-3303.
|
| [12] |
Shimada K, Skouta R, Kaplan A, et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis[J]. Nat Chem Biol, 2016, 12(7):497-503.
|
| [13] |
Gaschler MM, Andia AA, Liu H, et al. FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation[J]. Nat Chem Biol, 2018, 14(5):507-515.
|
| [14] |
Noubiap JJ. Shifting from quinine to artesunate as first-line treatment of severe malaria in children and adults: saving more lives[J]. J Infect Public Health, 2014, 7(5):407-412.
|
| [15] |
Eling N, Reuter L, Hazin J, et al. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells[J]. Oncoscience, 2015, 2(5):517-532.
|
| [16] |
Roh JL, Kim EH, Jang H, et al. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis[J]. Redox Biol, 2017(11):254-262.
|
| [17] |
Louandre C, Ezzoukhry Z, Godin C, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib[J]. Int J Cancer, 2013, 133(7):1732-1742.
|
| [18] |
Dixon SJ, Patel DN, Welsch M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis[J]. Elife, 2014(3):e02523.
|
| [19] |
Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression[J]. Nature, 2015, 520(7545):57-62.
|
| [20] |
Louandre C, Marcq I, Bouhlal H, et al. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells[J]. Cancer Lett, 2015, 356(2 Pt B):971-977.
|
| [21] |
Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells[J]. Hepatology, 2016, 63(1):173-184.
|
| [22] |
Sun X, Niu X, Chen R, et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis[J]. Hepatology, 2016, 64(2):488-500.
|
| [23] |
Shang Y, Luo M, Yao F, et al. Ceruloplasmin suppresses ferroptosis by regulating iron homeostasis in hepatocellular carcinoma cells[J]. Cell Signal, 2020(72):109633.
|
| [24] |
Bai T, Lei P, Zhou H, et al. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells[J]. J Cell Mol Med, 2019, 23(11):7349-7359.
|
| [25] |
Qi W, Li Z, Xia L, et al. LncRNA GABPB1-AS1 and GABPB1 regulate oxidative stress during erastin-induced ferroptosis in HepG2 hepatocellular carcinoma cells[J]. Sci Rep, 2019, 9(1):16185.
|
| [26] |
Tang H, Chen D, Li C, et al. Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells[J]. Int J Pharm, 2019(572):118782.
|
| [27] |
Ou W, Mulik RS, Anwar A, et al. Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma[J]. Free Radic Biol Med, 2017(112):597-607.
|
| [28] |
Zheng DW, Lei Q, Zhu JY, et al. Switching apoptosis to ferroptosis: metal-organic network for high-efficiency anticancer therapy[J]. Nano Lett, 2017, 17(1):284-291.
|